This segment explains the clinical significance of BRAF V600E–mutant NSCLC and highlights why early comprehensive genomic profiling is essential for identifying patients who benefit most from targeted BRAF/MEK inhibition.

Detailed discussion of Fitusiran, Marstacimab, and Concizumab, their mechanisms of action, differentiation from factor replacement, and highlights from key clinical trials (BASIS, ATLAS, Explorer 8).

Elacestrant significantly improved progression-free survival and maintained a manageable safety profile, especially benefiting patients with ESR1-mutated tumors.

Mark Nestor reveals groundbreaking insights on botulinum toxin's evolving science, enhancing its efficacy and expanding its medical applications in dermatology.

Discover how botulinum toxin injections in the glabella affect brain function, enhancing mood by altering emotional feedback from frowning.

Expert discusses how, despite its importance, albuminuria screening remains underutilized, and improving adherence to dual testing can transform early CKD detection.

Exploration of the emergence of nonfactor treatment classes, explaining how these agents function independently of missing clotting factors and their relevance to patient convenience, dosing, and efficacy.

Among chemotherapy-naive patients, elacestrant extended median progression-free survival compared with standard therapy, particularly in ESR1-mutated cases.

The EMERALD study carries significant implications across multiple stakeholders in ER+/HER2- metastatic breast cancer.